Concert Pharmaceuticals begins Phase l trial of CTP-543 to treat alopecia areata

Clinical stage, biopharmaceutical company Concert Pharmaceuticals has begun a Phase l clinical trial of CTP-543 to treat alopecia areata, an autoimmune disease that results in partial or complete loss of hair on the scalp.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news